BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Chronic Inflammatory Demyelinating Polyneuropathy readouts · 
 AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Chronic Inflammatory 
 Demyelinating Polyneuropathy\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06290141-11341@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20270709
DTEND;VALUE=DATE:20270710
SUMMARY:Riliprubart: Phase 3 readout est. (NCT06290141)
DESCRIPTION:Riliprubart\, phase 3\, Chronic Inflammatory Demyelinating Poly
 neuropathy.\nStudy: A Study to Test the Efficacy and Safety of Riliprubart
  Against the Usual Treatment of Intravenous Immunoglobulin (IVIg) in Peopl
 e With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)\nEstimated
  primary completion: 9 July 2027. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/riliprubart#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06290141
URL:https://assetmemo.bio/drug/riliprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07032662-10825@assetmemo.bio
DTSTAMP:20261121T005607Z
DTSTART;VALUE=DATE:20280831
DTEND;VALUE=DATE:20280901
SUMMARY:Imeroprubart: Phase 2 readout est. (NCT07032662)
DESCRIPTION:Imeroprubart\, phase 2\, Chronic Inflammatory Demyelinating Pol
 yneuropathy.\nStudy: Imeroprubart in Adult Participants With Chronic Infla
 mmatory Demyelinating Polyneuropathy (CIDP)\nEstimated primary completion:
  August 2028. This is a ClinicalTrials.gov estimate\, not a confirmed read
 out date\, and it can move.\nDrug page: https://assetmemo.bio/drug/imeropr
 ubart#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/N
 CT07032662
URL:https://assetmemo.bio/drug/imeroprubart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
